Cover Image
Market Research Report

Antibiotic Resistance Markets - Therapeutics. By Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides & Customization 2020 to 2024

Published by Howe Sound Research Product code 616480
Published Content info 411 Pages
Delivery time: 1-2 business days
Price
Back to Top
Antibiotic Resistance Markets - Therapeutics. By Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides & Customization 2020 to 2024
Published: November 3, 2019 Content info: 411 Pages
Description

OVERVIEW:

Antimicrobial Resistance is creating new kinds of infections and “superbugs” that are resistant to current antibiotic medicines. New technologies (and new drugs) are under development to capture this growing market. We have identified the 6 Key Large Opportunities in this space and developed market forecasts. We have looked at the technology picture too, giving you, plain language understanding of the different ways pathogens, and infections, can be treated, including an explanation of the key role diagnostics will play. This is a market with a lot of players, there are over 100 biotechnology companies profiled in the report. And we summarize what technologies they are using.

Our research makes you the expert in your organization. Get our research team working for you by ordering all, or a portion, of this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. We wrote this report and we are ready, by phone or email, to help you use it. As always, assistance, and additional specific data, is provided without additional charges.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School
Table of Contents

Table of Contents

i. Antimicrobial Resistance - Strategic Situation Analysis

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1 The Growing Threat and Opportunity of Antimicrobial Resistance
  • 1.2 Defining the Opportunity
    • 1.2.1 Revenue Market Size
  • 1.3 Methods and Sources
    • 1.3.1 Authors
    • 1.3.2 Sources
  • 1.4 U.S. Antibiotic Markets - Perspective
    • 1.4.1 U.S. Outpatient Use of Antibiotics
    • 1.4.2 U.S. Pharmaceutical Spending

2. Overview of a Dynamic Market

  • 2.1 Market Players - Roles & Impacts
    • 2.1.1 Drug manufacturers - Larger/pharmaceutical
    • 2.1.2 Drug manufacturers - Generic
    • 2.1.3 Contract Research and Manufacturing
    • 2.1.4 In Vitro Diagnostics Industry
    • 2.1.5 Drug Marketing Companies
    • 2.1.6 Biotechnology Companies
    • 2.1.7 Regulatory Bodies
  • 2.2 Understanding Antimicrobial Resistance
    • 2.2.1 What is Antimicrobial Resistance (AMR)
    • 2.2.2 Bacteria and Other Microbes
    • 2.2.3 The History of Antibiotics
    • 2.2.4 The Role of Animal Husbandry
    • 2.2.5 The Implications of Horizontal Transfer
    • 2.2.6 The Threat of AMR
  • 2.3 The Changing Road to New Antibiotics & Technologies
  • 2.4 The Key Role of Diagnostics in AMR

3. The Market Opportunity of AMR

  • 3.1 The Key Large Market Opportunities in AMR
    • 3.1.1 Streptococcus Pneumoniae (DRSP)
    • 3.1.2 Campylobacter (DRC)
    • 3.1.3 Clostridium Difficile (CD)
    • 3.1.4 Staphylococcus aureus (MRSA)
    • 3.1.5 Neisseria gonorrhoeae (DRNG)
    • 3.1.6 Salmonella (DRNTS)
  • 3.2 Therapeutic Technology Development Opportunities
    • 3.2.1 Using Viruses Against Bacteria
    • 3.2.2 Hydrolytic Enzymes Join the Fight
    • 3.2.3 Antibodies
    • 3.2.4 Vaccines
    • 3.2.5 Probiotic Technology
    • 3.2.6 Peptides vs. Pathogens
    • 3.2.7 Mining Obsolete Science
    • 3.2.8 CRISPR Antibiotics
  • 3.3. Antibiotic Resistance Recent Developments
    • 3.3.1 Recent Developments - Importance and How to Use This Section
    • 3.3.2 Importance of These Developments
    • 3.3.3 How to Use This Section
      • New class of antibiotics for AMR
      • New AMR Drug
      • CRISPR Modifies Phages to target Superbugs
      • Genetically Modified Phage Fights 'Superbug' Infection
      • NIH awards $33 million grant to develop new antibiotics
      • Bacteria found in ancient Irish soil halts growth of superbugs
      • OpGen Partners With NYS DOH, Merck Subsidiary for AMR Surveillance
      • New breakthrough in the war against antibiotic resistance
      • Amicrobe, Inc., patents AMR Gel
      • Microneedle Patch to Combat AMR
      • Antimicrobial peptides find application medium
      • Antibiotic shortages fuelling antimicrobial resistance

4. Key Biotechnology Companies and Their Technology

  • 4.2 Therapeutics
    • 4.2.1 The Medicines Company
    • 4.2.2 Melinta Therapeutics
    • 4.2.3 Arsanis
    • 4.2.4 Phage Technologies S.A
    • 4.2.5 Westway Health
    • 4.2.6 Tetraphase Pharmaceuticals
    • 4.2.7 BioVersys GmbH
    • 4.2.8 Nabriva Therapeutics
    • 4.2.9 Macrolide Pharmaceuticals
    • 4.2.10 Nemesis Bioscience
    • 4.2.11 C3J Therapeutics, Inc
    • 4.2.12 EpiBiome
    • 4.2.13 discuva
    • 4.2.14 SmartPhage
    • 4.2.15 AmpliPhi Biosciences
    • 4.2.16 Pherecydes Pharma
    • 4.2.17 Micreos
    • 4.2.18 Procarta Biosystems
    • 4.2.19 Lumavita
    • 4.2.20 Madam Therapeutics
    • 4.2.21 Priaxon
    • 4.2.22 Biolytx Pharmaceuticals
    • 4.2.23 AntibioTx
    • 4.2.24 Xellia Pharmaceuticals
    • 4.2.25 Paratek Pharmaceuticals
    • 4.2.26 Synereca Pharmaceuticals
    • 4.2.27 Allecra Therapeutics
    • 4.2.28 Fixed Phage
    • 4.2.29 Enanta Pharmaceuticals, Inc
    • 4.2.30 Demuris
    • 4.2.31 Prommune
    • 4.2.32 Biosergen
    • 4.2.33 Innovation Pharmaceuticals
    • 4.2.34 Aviragen Therapeutics
    • 4.2.35 Achillion Pharmaceuticals
    • 4.2.36 ImmunNovative Developments, S.L.
    • 4.2.37 Achaogen, Inc
    • 4.2.38 SelectX Pharmaceuticals, Inc.
    • 4.2.39 TaiGen Biotechnology Co., Ltd
    • 4.2.40 Theravance Biopharma
    • 4.2.41 Abbvie
    • 4.2.42 KYORIN Pharmaceutical Co.,Ltd.
    • 4.2.43 Iterum Therapeutics Limited
    • 4.2.44 Forge Therapeutics
    • 4.2.45 Alopexx Vaccine LLC
    • 4.2.46 Integrated Biotherapeutics
    • 4.2.47 Hennepin Life Sciences
    • 4.2.48 Fedora Pharmaceuticals Inc
    • 4.2.49 Contrafect Corporation
    • 4.2.50 Basilea Pharmaceutica Ltd.
    • 4.2.51 AiCuris
    • 4.2.52 RedHill Biopharma
    • 4.2.53 Redx Pharma Plc/ Redx Anti Infectives Ltd.
    • 4.2.54 ABAC Therapeutics
    • 4.2.55 Alaxia SAS
    • 4.2.56 Antabio S.A.S
    • 4.2.57 Auspherix Ltd
    • 4.2.58 BioFilm Pharma
    • 4.2.59 Centauri Therapeutics Ltd
    • 4.2.60 Combioxin SA
    • 4.2.61 Da Volterra
    • 4.2.62 Debiopharm International SA
    • 4.2.63 Deinobiotics/Deinove
    • 4.2.64 Destiny Pharma plc
    • 4.2.65 Eligo Bioscience
    • 4.2.66 Helperby Therapeutics Ltd
    • 4.2.67 Karveel Pharmaceuticals
    • 4.2.68 MaaT Pharma
    • 4.2.69 Motif BioSciences, Inc / Motif Bio PLC
    • 4.2.70 Mutabilis SAS
    • 4.2.71 Neem Biotech Ltd
    • 4.2.72 Northern Antibiotics Oy (Ltd)
    • 4.2.73 Nosopharm
    • 4.2.74 NovaBiotics Ltd
    • 4.2.75 Phico Therapeutics Ltd
    • 4.2.76 Polyphor Ltd
    • 4.2.77 QureTech Bio AB
    • 4.2.78 SetLance srl
    • 4.2.79 Ultupharma AB
    • 4.2.80 Vaxdyn
    • 4.2.81 Vibiosphen
    • 4.2.82 Bioaster
    • 4.2.83 Vivexia
    • 4.2.85 KBP Biosciences
    • 4.2.86 Absynth Biologics
    • 4.2.87 Spero Therapeutics
    • 4.2.88 Merck
    • 4.2.89 Symphogen
    • 4.2.90 Warp Drive Bio
    • 4.2.91 Johnson & Johnson (Janssen)
    • 4.2.92 Pfizer
    • 4.2.93 Allergan
    • 4.2.95 Novartis
    • 4.2.97 AstraZeneca
    • 4.2.100 Cipla
    • 4.2.101 DSM Sinochem Pharmaceuticals
    • 4.2.102 Wockhardt Ltd.
    • 4.2.103 VenatoRx Pharmaceuticals
    • 4.2.104 MicuRx
    • 4.2.105 Entasis Therapeutics
    • 4.2.106 Merlion Pharmaceuticals
    • 4.2.107 Aridis Pharmaceuticals Inc
  • 4.3 The Therapeutics Race - Summary of Companies Research Areas

5. Global Market Size

  • 5.1 Global Market by Country
  • 5.2 Global Market by Pathogen
  • 5.3 Global Market by Technology

7. Market Sizes by Pathogen

  • 7.1 DRSP Market
  • 7.2 DRC Market
  • 7.3 CD Market
  • 7.4 MRSA Market
  • 7.5 DRNG Market
  • 7.6 DRNTS Market
  • 7.7 Other Pathogen Market

8. Market Sizes by Technology

  • 8.1 Antibiotics Market
  • 8.2 Phage Market
  • 8.3 Pep/Lys Market
  • 8.4 Antibodies Market
  • 8.5 Vaccine Market
  • 8.6 Other Technology Market

9. The Future of AMR

Appendices

  • I. United States Medicare System: Top Selling Drugs 2011-2015

Table of Tables

  • Table 1 USA - Outpatient Use of Antibiotics by Class
  • Table 2 USA - Outpatient Use of Antibiotics Top 5
  • Table 3 Market Players by Type
  • Table 4 Known Human Pathogenic Diseases
  • Table 5 The Key Market Opportunities
  • Table 6 - Market Potential DRSP Therapeutic
  • Table 7 - Market Potential DRC Therapeutic
  • Table 8 Eight Technologies under development
  • Table 9 Antibodies Approved for Infectious Disease Treatment
  • Table 10 Therapeutic Technology Research - # of Companies
  • TABLE 11 GLOBAL MARKET BY COUNTRY
  • TABLE 12 GLOBAL MARKET BY PATHOGEN
  • TABLE 13 GLOBAL MARKET BY TECHNOLOGY
  • TABLE 14 DRSP SEGMENT BY COUNTRY
  • TABLE 15 DRC SEGMENT BY COUNTRY
  • TABLE 16 CD SEGMENT BY COUNTRY
  • TABLE 17 MRSA SEGMENT BY COUNTRY
  • TABLE 18 DRNG SEGMENT BY COUNTRY
  • TABLE 19 DRNTS SEGMENT BY COUNTRY
  • TABLE 20 OTHER PATHOGEN SEGMENT BY COUNTRY
  • TABLE 21 ANTIBIOTICS SEGMENT BY COUNTRY
  • TABLE 22 PHAGE SEGMENT BY COUNTRY
  • TABLE 23 PEP/LYS SEGMENT BY COUNTRY
  • TABLE 24 ANTIBODIES SEGMENT BY COUNTRY
  • TABLE 25 VACCINE SEGMENT BY COUNTRY
  • TABLE 26 OTHER TECHNOLOGY SEGMENT BY COUNTRY
  • Table 27 2011 to 2015 Top Selling Drugs

Table of Figures

  • Figure 1 Pharmaceutical Spending Trends
  • Figure 2 AMR and Antibiotic Introduction
  • Figure 3 The Death Toll of AMR
  • Figure 4 Phage T4 Anatomy and Infection Cycle
  • Figure 5 Key Global Markets
  • FIGURE 6 PATHOGEN SHARE BY YEAR
  • FIGURE 7 PATHOGEN SEGMENT GROWTH RATES
  • FIGURE 8 SEGMENT SHARE SHIFTS
  • Figure 9 Market Share Start Year
  • Figure 10 Market Share End Year
  • FIGURE 11 TECHNOLOGY SHARE BY YEAR
  • FIGURE 12 PATHOGEN SEGMENT GROWTH RATES
  • FIGURE 13 SEGMENT SHARE SHIFTS
  • Figure 14 Market Share Start Year
  • Figure 15 Market Share End Year
  • FIGURE 16 DRSP VS. TOTAL MARKET GROWTH
  • FIGURE 17 DRC VS. TOTAL MARKET GROWTH
  • FIGURE 18 CD VS. TOTAL MARKET GROWTH
  • FIGURE 19 MRSA VS. TOTAL MARKET GROWTH
  • FIGURE 20 DRNG VS. TOTAL MARKET GROWTH
  • FIGURE 21 DRNTS VS. TOTAL MARKET GROWTH
  • FIGURE 22 OTHER PATHOGEN VS. TOTAL MARKET GROWTH
  • FIGURE 23 ANTIBIOTICS VS. TOTAL MARKET GROWTH
  • FIGURE 24 PHAGE VS. TOTAL MARKET GROWTH
  • FIGURE 25 PEP/LYS VS. TOTAL MARKET GROWTH
  • FIGURE 26 ANTIBODIES VS. TOTAL MARKET GROWTH
  • FIGURE 27 VACCINE VS. TOTAL MARKET GROWTH
  • FIGURE 28 OTHER TECHNOLOGY VS. TOTAL MARKET GROWTH
Back to Top